Results 11 to 20 of about 45,519 (269)
Colchicine Impacts Leukocyte Trafficking in Atherosclerosis and Reduces Vascular Inflammation
Frontiers in Immunology, 2022 BackgroundInflammation strongly contributes to atherosclerosis initiation and progression. Consequently, recent clinical trials pharmacologically targeted vascular inflammation to decrease the incidence of atherosclerosis-related complications ...
Ulrike Meyer-Lindemann +23 more
doaj +2 more sources
Arthritis Research & Therapy, 2020 Background Colchicine is a widely used drug to treat inflammatory diseases. Due to its long historical use in medicine, controlled clinical trials have been small and there remains some caution with the use of this drug in patients with co-morbidities ...
Sarah Stewart +4 more
doaj +2 more sources
Colchicine: the good, the bad, the ugly and how to minimize the risks
Rheumatology, 2023 Colchicine has an important role in managing various conditions, including gout, familial Mediterranean fever, amyloidosis, Behçet’s syndrome, recurrent pericarditis and calcium pyrophosphate deposition disease.
L. Stamp +4 more
semanticscholar +1 more source
Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review
Acta Pharmacologica Sinica, 2022 Colchicine is an ancient herbal drug derived from Colchicum autumnale. It was first used to treat familial Mediterranean fever and gout. Based on its unique efficacy as an anti-inflammatory agent, colchicine has been used in the therapy of cardiovascular
Fan Zhang +5 more
semanticscholar +1 more source
Radioimmunoassay of colchicine [PDF]
Biochemical Journal, 1975 Antibodies to cholchicine were raised in rabbits after injection of N-desacetylthiocolchicine conjugated to bovine serum albumin. Antisera diluted 1:100 bound 50% of 1.6ng of [3H]colchicine. Cross-reaction of the antisera with colchicine derivatives and other drugs was measured and a radioimmunoassay of colchicine in biological fluids was proposed.
Duprey F, Bohuon C, Boudène C
openaire +3 more sources
JAMA Network Open, 2020 Key Points Question Is the receipt of colchicine among patients hospitalized with symptomatic coronavirus disease 2019 associated with clinical benefit?
S. Deftereos +48 more
semanticscholar +1 more source
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2022 Background Dilated cardiomyopathy remains a leading cause of heart failure worldwide. Immune inflammation response is recognized as a significant player in the progression of heart failure; however, immunomodulatory strategies remain a long‐term ...
Xuan Sun +6 more
semanticscholar +1 more source
The Ugly Side of Colchicine [PDF]
Journal of Investigative Medicine High Impact Case Reports, 2021 We report a rare case of a 32-year-old male who ingested 32.4 to 54 mg of colchicine and presented after 44 hours. He developed progressive multiple organ failure with shock, acute kidney failure, troponemia, pancytopenia, absolute neutropenia, disseminated intravascular coagulation, acute liver failure, rhabdomyolysis, and lactic acidosis.
Justin Cozza +3 more
openaire +3 more sources
Frontiers in Pharmacology, 2019 Objectives: A previous study suggested that colchicine may cause leukopenia and increase the risk of infection, such as pneumonia. Thus, we investigated the potential relationship between colchicine use and risk of developing pneumonia.Methods: Data were
Tsung-Lin Tsai +8 more
doaj +1 more source
Colchicine reduces atherosclerotic plaque vulnerability in rabbits
Atherosclerosis Plus, 2021 Background and aims: The anti-inflammatory agent colchicine is gaining interest as a treatment for coronary artery disease. However, the effects of colchicine in atherosclerotic animal models are mostly unknown. This study aimed to evaluate colchicine in
François Roubille +12 more
doaj +1 more source